Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Eli Lilly introduces its Mounjaro Kwikpen in India at ₹14,000 for the 2.5 mg starting dose, competing with Novo Nordisk’s Wegovy in the booming GLP-1 drug market for diabetes and weight loss.